Extensive disease per criteria of the International Association for the Study of Lung Cancer (IASLC)-American Joint Committee on Cancer (AJCC) TNM staging system
Histologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system
Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), or next generation sequencing (NGS) via a Clinical Laboratory Improvement Act (CLIA)-certified local diagnostic test (LDT); OR
Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC (American Joint Committee on Cancer version 8)
Stage II/III disease as per American Joint Committee on Cancer (AJCC) staging 7.0\r\n* Baseline imaging with standard of care fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) scan and endoscopic ultrasound within 28 days prior to registration
American Joint Committee on Cancer (AJCC) (2009) stage IV melanoma, or stage III melanoma not curable by surgery and which is progressing; patients must have at least 1 target lesion measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Subjects with stage IV non-small cell lung cancer as defined by American Joint Committee on Cancer (AJCC).
Patients must have American Joint Committee on Cancer (AJCC) (2010) clinical stage T3-4, N0-1, M0 disease
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) (8th edition) staging criteria:\r\n* AJCC stage IV (Tany, Nany, M1a(1), M1b(1), M1c(1) or M1d(1))\r\n* AJCC stage IIIC (at least N2b) or IIID with unresectable nodal/locoregional involvement
Diagnosis of advanced/unresectable melanoma (American Joint Committee on Cancer [AJCC] v.8 stage 3C/D/4)
Final American Joint Committee on Cancer (AJCC) version 7.0 stage 0-IIB (pathologic stage Tis, T1-T3, all must be N0 and M0 status)
History of another cancer within 3 years before enrollment with the exception of nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor.
Stage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria.
Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] version 7.0 Staging manual) NSCLC
Metastatic (American Joint Committee on Cancer [AJCC] stage IV) RCC
Disease eligibility and stage\r\n* Histologically confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or renal carcinoma\r\n* Previously treated or previously untreated stage IV melanoma, stage IV lung cancer, and metastatic renal cancer by American Joint Committee on Cancer (AJCC) staging criteria\r\n* Presence of a lesion that is suitable for hypofractionated radiotherapy
Did not achieve pathological complete response (pCR) to any chemotherapy that was given with the intention to induce best response prior surgery. pCR is defined as the current American Joint Committee on Cancer (AJCC) breast cancer staging.
Presumed American Joint Committee on Cancer (AJCC) tumor stage I or II
Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] staging manual) NSCLC
American Joint Committee on Cancer (AJCC) stage 3 or 4 histologically proven NSCLC not amenable to curative therapy
Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7) non-small cell lung cancer
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria:\r\n* AJCC stage IV (T any, N any, M1a, b, or c)\r\n* AJCC stage IIIB or IIIC with unresectable nodal/locoregional involvement
American Joint Committee on Cancer (AJCC) clinical stage T2-T3 N0M0
Appropriate staging studies identifying as American Joint Committee on Cancer (AJCC) stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less
History of another invasive cancer within 5 years with the exceptions of nonmelanoma skin cancers and American Joint Committee on Cancer (AJCC) stage 0 or 1 cancers that have a remote probability of recurrence in the opinion of the investigator
Diagnosis of melanoma belonging to the following American Joint Committee on Cancer (AJCC) TNM stages:\r\n* Tx or T1-4 and\r\n* N1b, or N2b, or N2c, or N3 and \r\n* M0
Stage IV cancer by American Joint Committee on Cancer (AJCC) staging criteria (except for pancreatic cancer cohort)
American Joint Committee on Cancer (AJCC) T1 or T2; N0 or N1microscopic (mic); stage IA-IIA breast cancer
Stage IV (American Joint Committee on Cancer [AJCC]) breast cancer patients who have failed at least one conventional therapy for metastatic disease
Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0-1 being eligible; and have a primary tumor of the pancreas (i.e., pancreatic head, neck, uncinate process, body/tail
Have a history of surgically resected and pathologically proved American Joint Committee on Cancer (AJCC) stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreas
Has a histologically- or cytologically-confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for advanced disease
Clinical stages IIA –IIIC (American Joint Committee on Cancer [AJCC] 2009)
Patients must have American Joint Committee on Cancer (AJCC) stage IIIC unresected or IV disease
Stage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic)
Participants who have been diagnosed with clinical or pathologic stage IB to stage IIIA adenocarcinoma of the breast (any subtype) who have undergone, and recovered from primary therapy (any combination of surgery, radiation, and/or chemotherapy and/or trastuzumab used to treat newly diagnosed disease), with their last dose/treatment (of any single or combination treatment) being between 45 days and 6 months (180 days) prior to enrollment; staging will be based on the Seventh Edition American Joint Committee on Cancer (AJCC) staging system; (systemic staging with computed tomography [CT] or positron emission tomography [PET] scans is not required by AJCC and is not required nor exclusionary for this trial)
Pathologically (histologically) proven diagnosis of primary carcinoma of the bladder (transitional cell cancer) within 8 weeks of registration; operable patients whose tumors are primary carcinomas of the bladder and exhibit histologic evidence of muscularis propria invasion and are American Joint Committee on Cancer (AJCC) clinical stages T2-T4a, Nx or N0, M0
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 E or K mutation determined by pyrosequencing assay or Food and Drug Administration (FDA)-approved equivalent test, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria: \r\n* AJCC stage IV (Tany, Nany, M1a, b, or c) \r\n* AJCC stage III B or C with unresectable nodal/locoregional involvement
Unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer staging system not amenable to local therapy.
Has locally advanced/metastatic disease, i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer (AJCC) or have recurrent disease.
Has locally advanced/metastatic disease (i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer) or has recurrent disease.
Male or female patients with metastatic, histologically- or cytologically-confirmed unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) of squamous histology (Staging per American Joint Committee on Cancer [AJCC], Edition 7). Mixed histology adenosquamous NSCLC will also be permitted.
Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that is unresectable or metastatic
Staging MRI must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c;
Pre- or post-menopausal women with stage II-III breast cancer (American Joint Committee on Cancer [AJCC] 2002)
Have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.
Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system
Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria
Staging studies must identify patient as American Joint Committee on Cancer (AJCC) stage I or II based on only 1 of the following combinations of primary tumor, regional lymph nodes, and distant metastases (TNM) staging:\r\n* T1, N0, M0\r\n* T2 (=< 7 cm), N0, M0\r\n* T3 (=< 7 cm), N0, M0
Stage T1-2N1-2c/T3-4N0-2c disease, as defined by American Joint Committee on Cancer (AJCC) criteria
Eligible patients must have appropriate staging studies identifying them as American Joint Committee on Cancer (AJCC) stage T1 (a, b, or c) or T2 (a, b, or c) adenocarcinoma of the prostate gland; the patient should not have direct evidence of regional or distant metastases after appropriate staging studies; histologic confirmation of cancer will be required by biopsy performed within 180 days of registration
Subjects with recurrent or refractory, metastatic disease (N1 or M1) fulfilling any of the following combinations of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging version 2010 and Fuhrman nuclear grading
Stage Tis, T1, or T2 laryngeal squamous cancer as defined by American Joint Commission on Cancer (AJCC) 2007 staging system
Cancer should be staged via American Joint Committee on Cancer (AJCC) as stage II, III, IVa, or IVb
Clinical stage T1N0M0 (by American Joint Committee on Cancer [AJCC] 2010 criteria)\r\n* Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or micronodular features must be =< 1 cm
Has a histologically-confirmed, unresectable or metastatic (Stage IV American Joint Committee on Cancer [AJCC seventh edition]) colorectal cancer (CRC)
American Joint Committee on Cancer (AJCC [2009]) stage IIIC cutaneous melanoma rendered free of disease by surgical resection no greater than 90 days prior study enrollment; patients with unknown primaries will be eligible for this trial; patients with a history of resected stage I or II cutaneous melanoma who subsequently have their first disease recurrence meeting the criteria for stage IIIC disease will also be eligible for this trial
Patients with recurrent, inoperable stage III, IV, M1a, b or c melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (American Joint Committee on Cancer [AJCC]); previously treated with any form of therapy (including chemotherapy, radiation therapy, immunotherapy or surgery) for either metastatic, relapsed, or primary melanoma are eligible for this trial, provided the previous treatment was completed > 30 days prior to enrollment
Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria
Patients with American Joint Committee on Cancer (AJCC) seventh edition stage 4 metastatic non-small cell lung carcinoma
Has extensive-stage disease defined as Stage IV (T any, N any, M 1a/b) by the American Joint Committee on Cancer (AJCC), Seventh Edition
Has previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee of Cancer (AJCC) staging criteria for breast cancer as assessed by the investigator based on radiological and/or clinical assessment:
Patient must be American Joint Committee on Cancer (AJCC) stage III (T3N0, T1-2N1) or stage IVa (T1-4N2-3M0, T4N0-1 M0) or stage IVb (unresectable disease) and be either unresectable or borderline resectable
Histological diagnosis of unresectable American Joint Committee on Cancer (AJCC) stage III or stage IV, v-raf murine sarcoma viral oncogene homolog B1 V600E/K mutation (BRAFV600E/K) mutant melanoma by a Clinical Laboratory Improvement Assessment (CLIA) approved test
Histological or cytological diagnosis of squamous cell carcinoma (SCC) of head and neck with American Joint Committee on Cancer (AJCC) Stage III, IVA or IVB and not amenable to surgical resection or locoregional radiation therapy with curative intent.
Stage IIIB disease not amenable to surgery or curative intent. Note: It is permissible to use either AJCC Version 6.0 or the AJCC Version 7.0 staging system. For sites that use AJCC Version 7.0, T4M0 patients with other ipsilateral nodules and N0-N2 are still eligible.
Pts undergoing extrapleural pneumonectomy without PDT for MPM or stage IV (M1A) NSCLC (after American Joint Committee on Cancer [AJCC] staging change 2010) or stage IIIB (before staging change) with malignant pleural effusion treated at Ohio State University (OSU) from 2005-2012
Histologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).
Patients must have histologically or cytologically confirmed metastatic melanoma; this includes American Joint Committee on Cancer (AJCC) stage IV or advanced/inoperable stage III; this also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases
Histologically or cytologically documented, locally advanced or metastatic (i.e., stage IIIB not eligible for definitive chemoradiotherapy, stage IV, or recurrent) NSCLC (per the American Joint Committee [AJCC] staging system)
Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
Cancer should be staged via American Joint Committee on Cancer (AJCC) as IIIA or IIIB
Cancer should be staged via American Joint Committee on Cancer (AJCC) as IIA, IIB, or III (T3 or T4, any N, M0)
Patients must have histologically or cytologically confirmed metastatic melanoma (includes American Joint Committee on Cancer [AJCC] stage IV or advanced/inoperable stage III; also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases)
Histologically confirmed cutaneous melanoma with unresectable stage III disease, or stage IV disease by American Joint Committee on Cancer (AJCC) criteria
Patients must have metastatic malignant melanoma or metastatic renal cell cancer (American Joint Committee on Cancer [AJCC] stage IV [M1] or equivalent disease); metastatic renal cell cancer patients must either have refused treatment with, have been unable to tolerate or have experienced progressive disease after treatment with sorafenib or sunitinib, and temsirolimus
Advanced (stage IIIB or IV) lung adenocarcinoma diagnosed by biopsy of the primary or metastatic site (American Joint Committee on Cancer 7.0)
Prostate cancer, with organ-localized disease with very low risk of disease recurrence, as indicated by stage pT2, N0, M0 lesions (if American Joint Committee on Cancer [AJCC] staging is not available in medical records, the investigators will infer the staging based on extensive review of the pathology report), combined Gleason score of 7 (3+4) or less, and preoperative PSA < 10 ng/ml
History of another invasive cancer within 5 years of randomization with the exceptions of (a) non-melanoma skin cancers and (b) American Joint Committee on Cancer (AJCC) stage 0 or 1 cancers that have a remote probability of recurrence, in the opinion of the treating physician, in consultation with the principal investigator
Stage 3 or 4 under the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (IUCC) staging system OR patients with stage 1 or 2 disease who will receive radiation equivalent to patients with stage 3 or 4 disease
Patients with American Joint Committee on Cancer (AJCC) stage II-IV head and neck squamous cell carcinoma who are beginning first-line non-surgical treatment with concurrent chemoradiotherapy (CCRT) and who are capable of understanding and adhering to the protocol requirements
Patients must have limited disease SCLC after clinical staging evaluation: clinical tumor, lymph nodes, metastasis (TNM) stages I-IIIB (i.e., confined to one hemithorax, but excluding T4 tumor based on malignant pleural effusion and N3 disease based on contralateral hilar or contralateral supraclavicular involvement) according to American Joint Committee on Cancer (AJCC) 1997 staging manual to be consistent with Radiation Therapy Oncology Group (RTOG) 0212
American Joint Committee on Cancer (AJCC) stage I to IV lung cancer requiring radiation therapy (3-dimensional [3D] conformal or stereotactic) or systemic therapy, with or without surgery
American Joint Committee on Cancer (AJCC) stage I, II, III or IV non-small-cell lung cancer as well as distant metastasis within the lung to be treated using radiotherapy will be eligible for this study
Patients who have undergone pathology review of their prostate biopsy at Emory University, Grady Memorial Hospital, Saint Joseph’s Hospital, and Atlanta VA Medical Center with American Joint Committee on Cancer (AJCC) clinical stage T1-T2 prostate cancer by physical exam.
American Joint Committee on Cancer (AJCC) stage 1, 2, 3 breast carcinoma
Has histologically confirmed, unresectable Stage III or Stage IV melanoma per the American Joint Committee on Cancer (AJCC) staging system.
Histologically or cytologically confirmed stage IV (metastatic) NSCLC as defined by American Joint Committee on Cancer (AJCC); recurrent but not metastatic disease is allowed if deemed incurable
Histologically or cytologically confirmed stage III-IV (non-metastatic) SCCHN as defined by American Joint Committee on Cancer (AJCC); nasopharyngeal cancer patients will be excluded; note that in rare instances, a cancer may be clearly invasive on imaging, but pathology may not be definitive (e.g. in-situ carcinoma); in such cases, the patient will be eligible if the unanimous opinion of the institutional tumor board is that the situation is definitive for invasive SCCHN
